SavedAdd your journal

Journals / Journal of Medicine and Palliative Care / 2026 / Volume: 7 Issue: 1

Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder

Serkan Kapancık(TIP FAKÜLTESİ)0000-0003-3019-4275
Elif Abanoz(SIVAS CUMHURIYET UNIVERSITY)0000-0002-9214-4735
Ahmet Ozan Kaleci(SIVAS CUMHURIYET UNIVERSITY)0000-0003-4514-6209
Pages
—
Publication Date
2026-02-20
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Because increased ADA activity levels lead to an imbalance in the purinergic signaling system, and increased XO activity leads to an increase in reactive oxygen species. may contribute to the development of anxiety in children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Anxiety disorders are quite common in children and adolescents.
📊
Key Findings & Data:Affecting approximately 6.5% of children and adolescents, this disorder stems from a complex interplay of genetic predisposition and environmental risk factors.
💡
Conclusion & Impact:Conclusion: Because increased ADA activity levels lead to an imbalance in the purinergic signaling system, and increased XO activity leads to an increase in reactive oxygen species. may contribute to the development of anxiety in children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anxiety disorder · adenosine deaminase · xanthine oxidase

Abstract

Aims: Anxiety disorders are quite common in children and adolescents. Affecting approximately 6.5% of children and adolescents, this disorder stems from a complex interplay of genetic predisposition and environmental risk factors. Since adenosine has a role in suppressing anxiety, increased adenosine degradation, followed by increased degradation of hypoxanthine and xanthine, and subsequently increased reactive oxygen species, which are associated with anxiety, may contribute to the biology of anxiety in children. Therefore, in our study, we aimed to investigate the activity levels of the adenosine degrading enzyme adenosine deaminase (ADA) and the hypoxanthine and xanthine degrading enzyme xanthine oxidase (XO) to determine whether changes in the activity of these two enzymes play a role in anxiety in children. Methods: The study design was a cross-sectional case-control study. ADA and XO enzyme activity levels were spectrophotometrically analyzed in serum samples obtained from children with anxiety and children in the control group. Results: ADA activity was measured as 22.12±2.51 U/L in children with anxiety, while this value was determined as 14.90±1.98 U/L in the control group (p<0.001). XO activity was found to be 5.38±0.86 U/L in children with anxiety and 4.24±0.62 U/L in the control group (p<0.001). Conclusion: Because increased ADA activity levels lead to an imbalance in the purinergic signaling system, and increased XO activity leads to an increase in reactive oxygen species. may contribute to the development of anxiety in children.

🔖

Cite This Article

Kapancık, S., Abanoz, E., Kaleci, A. O. (2026). Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. Journal of Medicine and Palliative Care, Volume: 7 Issue: 1. https://doi.org/10.47582/jompac.1864383

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA., Ahbabi AA. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30(1):30-44. doi:10.1186/s43045-023-00315-3
  2. Michael T, Zetsche U, Margraf J. Epidemiology of anxiety disorders. Psychiatry. 2007;6(4):136-142. doi:10.1016/j.mppsy.2007.01.007
  3. Rapee RM, Creswell C, Kendall PC, Pine DS, Waters AM. Anxiety disorders in children and adolescents: a summary and overview of the literature. Behav Res Ther. 2023;168:104376. doi:10.1016/j.brat.2023.104376
  4. Lewinsohn PM, Gotlib IH, Lewinsohn M, Seeley JR, Allen NB. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol. 1998;107(1):109-117. doi:10.1037/0021-843X.107.1.109
  5. Meier SM, Deckert J. Genetics of anxiety disorders. Curr Psychiatry Rep. 2019;21(3):16. doi:10.1007/s11920-019-1002-7
  6. Cheffer A, Castillo ARG, Corrêa-Velloso J, et al. Purinergic system in psychiatric diseases. Mol Psychiatry. 2018;23(1):94-106. doi:10.1038/mp. 2017.188
  7. Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol. 2008;8(1):2-7. doi:10.1016/j.coph.2007.09.002
  8. Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M. The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung. 2012;14(4):231-238.
  9. Cristalli G, Costanzi S, Lambertucci C, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev. 2001;21(2):105-128. doi:10.1002/1098-1128
  10. Kostić DA, Dimitrijević DS, Stojanović GS, Palić IR, Đorđević AS, Ickovski JD. Xanthine oxidase: isolation, assays of activity, and inhibition. J Chem. 2015;2015(1):294858. doi:10.1155/2015/294858
  11. Pasquini S, Contri C, Merighi S, et al. Adenosine receptors in neuropsychiatric disorders: fine regulators of neurotransmission and potential therapeutic targets. Int J Mol Sci. 2022;23(3):1219. doi:10.3390/ijms23031219
  12. Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol. 2014;119:373-393. doi:10.1016/B978-0-12-801022-8.00015-5
  13. Prediger RD, da Silva GE, Batista LC, Bittencourt AL, Takahashi RN. Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. Neuropsychopharmacology. 2006;31(10):2210-2220. doi:10.1038/sj.npp. 1301001
  14. Fedoce ADG, Ferreira F, Bota RG, Bonet-Costa V, Sun PY, Davies KJ. The role of oxidative stress in anxiety disorder: cause or consequence? Free Radic Res. 2018;52(7):737-750. doi:10.1080/10715762.2018.1475733
  15. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009;2(2):63-67. doi:10.4161/oxim.2.2.7944
  16. Giusti G, Galanti B. Colorimetric method. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Vol 3. Weinheim: Verlag Chemie; 1984: 315-323.
  17. Massey V, Brumby PE, Komai H, Palmer G. Studies on milk xanthine oxidase: some spectral and kinetic properties. J Biol Chem. 1969;244(7): 1682-1691. doi:10.1016/S0021-9258(18)91738-2
  18. Herken H, Akyol O, Yilmaz HR, et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol. 2006;21(1): 53-59. doi:10.1002/hup.742
  19. Yarpuz AY, Yilmaz A, Soykan A, Elgün S, Kumbasar H. Levels of adenosine deaminase and dipeptidyl peptidase IV in patients with panic disorder. Turk Psikiyatri Derg. 2008;19(2):1-7.
  20. Michel TM, Camara S, Tatschner T, et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychia. 2010; 11(2–2):314-320. doi:10.3109/15622970802123695
  21. Cieślak M, Czarnecka J, Roszek K. The roles of purinergic signaling in psychiatric disorders. Acta Biochimica Polonica. 2016;63(1):1-9. doi:10. 18388/abp.2015_1004
  22. Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol. 2002;54(4):313-326.
  23. Han C, Wu Y, Rong J, Xia Q, Du D. Unveiling the Emerging role of xanthine oxidase in acute pancreatitis: beyond reactive oxygen species. Antioxidants. 2025;14(1):95. doi:10.3390/antiox14010095
  24. Krolow R, Arcego DM, Noschang C, Weis SN, Dalmaz C. Oxidative imbalance and anxiety disorders. Curr Neuropharmacol. 2014;12(2):193-204. doi:10.2174/1570159X11666131120223530
  25. Guney E, Ceylan MF, Tektas A, et al. Oxidative stress in children and adolescents with anxiety disorders. J Affect Disord. 2014;156:62-66. doi: 10.1016/j.jad.2013.11.016